Literature DB >> 7768107

Ocular distribution of the chimeric protein IL2-PE40.

D BenEzra1, G Maftzir, E Hochberg, I Anteby, H Lorberboum-Galski.   

Abstract

A construct of IL-2 and pseudomonas exotoxin (PE40) has been genetically engineered. An aliquot of 100 microliter of the chimeric protein, radiolabelled with I125, was administered to healthy rats by various routes. At different intervals, ocular and non ocular tissues were removed and the levels of the radiolabelled chimeric protein IL-2-PE40 measured. Systemic administration of IL2-PE40 either intravenously (IV) or intraperitoneally (IP) leads to high levels of the drug in the blood, liver and spleen. Little or no radioactivity is observed within the ocular tissues using this route. On the other hand, local administration of the drug either as subtenon injection or as eye drops resulted in a very high concentration of the drug within the conjunctiva, cornea and sclera, with little radioactivity detected systemically. Subtenon injection induced a significant drug level within the optic nerve. With the drops, the chimeric protein was also detected, in low levels, intraocularly.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7768107     DOI: 10.3109/02713689508999927

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.555


  3 in total

1.  The association between dietary patterns and a doctor diagnosis of systemic lupus erythematosus: the Adventist Health Study-2.

Authors:  Jisoo Oh; Keiji Oda; Marissa Brash; W Lawrence Beeson; Joan Sabaté; Gary E Fraser; Synnove F Knutsen
Journal:  Lupus       Date:  2022-07-02       Impact factor: 2.858

Review 2.  Ocular delivery of macromolecules.

Authors:  Yoo Chun Kim; Bryce Chiang; Xianggen Wu; Mark R Prausnitz
Journal:  J Control Release       Date:  2014-07-03       Impact factor: 9.776

3.  Intravital Multiphoton Microscopy of the Ocular Surface: Alterations in Conventional Dendritic Cell Morphology and Kinetics in Dry Eye Disease.

Authors:  Arsia Jamali; Yashar Seyed-Razavi; Cecilia Chao; Gustavo Ortiz; Brendan Kenyon; Tomas Blanco; Deshea L Harris; Pedram Hamrah
Journal:  Front Immunol       Date:  2020-05-07       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.